Closing Remarks -Professor Peter Sever
This symposium provided a remarkable opportunity to review a wealth of experimental and clinical data on angiotensin II and AT-1 antagonists, in general, and candesartan, in particular. I have personally been pleased to have an opportunity to see some exciting new data, which illustrated to me the depth and extent of research occurring throughout the world into these agents. We heard updated information from Thomas Unger detailing the pharmacology of the angiotensin II type 1 and type 2 receptors. It has been shown that most of the known effects of angiotensin are mediated by AT 1 receptors, while much less is known about the role of the AT 2 receptors. Recent results reported in this meeting suggest that AT 2 receptors are involved in the differentiation, development and apoptosis in various tissues, including the vascular system. Professor Unger stressed that the balance between AT 1 and AT 2 receptors may be of critical importance, with AT 1 -receptor antagonists used as antihypertensive drugs, unmasking AT 2 -receptors and revealing effects of angiotensin II on cellular function that are not obvious under physiological circumstances.
Professor Miyazaki provided an excellent overview of ACE inhibitors versus angiotensin II receptor antagonists looking at the role of chymase in angiotensin II production. His results indicated that the action of ACE inhibitors may be influenced by angiotensin II production, via alternative pathways (chymase) whereas the action of angiotensin II antagonists are independent of the pathway of angiotensin II production. Results of this kind can have important consequences in differentiating between these two classes of agents.
To delineate the appropriate use of the AT 1 antagonist, candesartan in the clinical setting, Professor Ogihara presented his results from an analysis of 14 multicentre studies assessing the clinical efficacy of this drug in Japan. He reported that candesartan, 4 -12 mg once daily, was effective and well tolerated in patients with both mild, moderate and severe hypertension, as well as those patients with renal insufficiency, and advocated its use as a first-line antihypertensive agent.
Of particular interest were reports assessing the influence of angiotensin II receptor antagonists on the response to vascular injury and the responses of the heart to cardiac mechanical stretch, presented by Dr Yamazaki. He found that mechanical stretch stimulates secretion and production of angiotensin II and endothelin-1 in cultured cardiomyocytes, and that these vasoconstrictive peptides may play an important role in mechanical stress-induced cardiac hypertrophy. Professor Mallion added to this data with evidence detailing the effect of these antihypertensive agents on cardiac and vascular remodelling.
Professor Brenner presented impressive data on the renoprotective effects of these drugs in animal models, of some early human data and renal injury. This was followed by evidence from Professor Kurokawa that there may be more than simply metabolic neutrality with these compounds and that they may have a role in reversing the state of insulin resistance that is such a common problem in patients with hypertension.
In summary, this symposium offered us the opportunity of reviewing the latest preclinical data emerging about angiotensin II receptor antagonists, as well as the clinical experience with candesartan in Japan, Europe and the United States.
I would like to thank all of the contributors for their excellent presentations which engendered so much interest. The high degree of research taking place is sure to lead to further breakthroughs in elucidating the action and role of these agents, and I keenly await the next symposium in this series to keep up-to-date with this rapidly moving field. I would also like to take this opportunity to thank Takeda Chemical Industries Ltd, for their unrestricted educational grant which made this symposium possible.
